Abstract:Introduction Amyloid transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, systemic, life-threatening disease, characterized by both cardiac and extra-cardiac symptoms and signs. Its diagnosis remains challenging, however it is increasingly being pursued due to the availability of non-invasive diagnostic means, namely bone scintigraphy. Data regarding the prevalence of ATTR-CM in Greece are scarce. Purpose We aimed to study the prevalence and characteristics of ATTR-CM, both wild-type (ATTRwt-CM) and hereditary (ATTRv-CM), in patients with left ventricular hypertrophy (LVH) of undetermined etiology in Greece. Methods RETTRACE is an on-going, low- risk, prospective, multicenter, nationwide descriptive study, in 14 major outpatient Cardiology centers throughout Greece. Its primary endpoint is the prevalence of ATTR-CM in adults ≥ 50 years, with: a) Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and a left ventricular wall thickness (LVWT) of ≥12mm, or b) a LVWT ≥14 mm of unknown etiology. Secondary endpoints include the prevalence of ATTRv-CM, the description of clinical characteristics of ATTR-CM patients, and their quality of life, as evaluated with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the EuroQol-5-Dimensions Questionnaire (EQ-5D-3L). Patients were screened and managed according to local clinical practice. Screening for light chain (AL) amyloidosis was done by immunofixation electrophoresis (serum and urine) and serum free light-chain (sFLC) assay, while biopsy was performed at the investigator's discretion. TTR genotyping was done centrally. Results The RETTRACE interim analysis (data-cut-off: May 31st, 2023), includes 153 patients (men: 52,9%), with a mean (SD) age of 77 (10.3) years. Basic demographics are shown in Table 1. Amongst patients who had bone scintigraphy results available, 71 (51.4%) were grade 0 according to the Perugini score. Furthermore, 62 tests of grades 1-3 were assessed by two independent reviewers and their final consensus was used to estimate the primary endpoint. In total, 24 out of 134 eligible patients were deemed to have ATTR-CM (17.9%), per applied criteria. Two of them carried mutations (Val114Ala and Ala101Thr respectively). As compared to non-ATTR-CM patients, those with ATTR-CM were older (mean age of 82.9 vs 76.0 years, p=0.004), less frequently hypertensive (54.2% vs 78.2%, p=0.021) and had more frequently undergone carpal tunnel surgery (29.2% vs 10.0%, p=0.021). Moreover, they had a poorer quality of life by MLHFQ (median 19.5 vs 40.0, p=0.05), while no significant differences were found in the EQ-5D-3L questionnaire. Conclusions ATTR-CM has a significant prevalence in a Greek population of adults ≥ 50 years with LVH of undetermined etiology. RETTRACE study results will provide valuable information for this underdiagnosed, life-threatening condition.

Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis

Prevalence, Characteristics and Outcomes of Older Patients with Hereditary versus Wild‐Type Transthyretin Amyloid Cardiomyopathy

Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis

Assessing Screening For Transthyretin Cardiac Amyloidosis Among Patients At A Safety Net Hospital In Metro Atlanta

Phenotypic presentation of family members of ATTRv probands and subsequent disease penetrance

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

Phenotype and prognostic factors in geriatric and non‐geriatric patients with transthyretin cardiomyopathy

Advanced Echocardiographic Assessment in Transthyretin Amyloidosis: Early Phenotype Markers in Mutation Carriers

Cardiac transthyretin amyloidosis in patients with conduction system disease

Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis

Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis

Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years

Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE Study

Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

Insights into cardiac amyloidosis screening in TAVI from a Greek/Cypriot Cohort: the GRECA-TAVI registry

Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

A phenomap of TTR amyloidosis to aid diagnostic screening

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy